We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks. In this ...

Schizophrenia cases associated with problematic weed use have skyrocketed in the wake of Canada's legalization of marijuana, ...

Yeah Cobenfy which is about schizophrenia, first new drug in thirty years.” Overall, BMY ranks 8th on our list of stocks Jim Cramer discusses. While we acknowledge the potential of BMY as an ...

British drug companies are making a new assault on schizophrenia, with about 16 novel medicines in the pipeline. A number of experimental drugs are designed to alter the chemistry of brain regions ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia ... of all marketed drugs, and Boehringer adds to a growing list of partners that ...

Atypical antipsychotic drugs have been shown to be more efficacious in treating cognitive disturbances of schizophrenia compared with typical antipsychotic drugs. Serotonin (5-hydroxytryptamine [5 ...

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers’ count, ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

Background: There is a growing amount of evidence suggesting that immunity and inflammation play an important role in the pathophysiology of schizophrenia. In this study, we aimed to examine the ...

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.